PHILADELPHIA, April 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), and nSpire Health, Inc. announced today their alliance to provide integrated Cardiac Safety and Pulmonary Core Lab Services to clinical researchers worldwide.
eResearchTechnology is a leading provider of centralized electrocardiographic (ECG), eClinical technology, ePRO, and other services to the pharmaceutical, biotechnology, medical device, and related industries. nSpire Health is a leading provider of respiratory clinical trials services, including Cardiopulmonary Exercise Testing, High Definition Pulmonary Diagnostics Systems, Spirometry, and Home Monitoring.
Under the agreement, eRT and nSpire will deliver a combined solution to meet the increased demand for cardio-pulmonary safety and efficacy services during clinical trials, in part caused by an increased interest in using inhaled therapeutics. The partnership will offer integrated services from project planning and set-up through study conduct, management, and data delivery for primary and secondary Cardiac and Respiratory clinical trial endpoints. nSpire Health will provide eSP(TM) Core Lab Data Management software, QA services, HDpft(TM), KoKo(R), PiKo(R), and PiKoLogic(TM) (electronic Diary) respiratory diagnostic measuring instruments. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT 2.0 workflow-enabled data management system.
"This alliance addresses a growing need in clinical research to offer comprehensive, best in class services in these two closely related areas of clinical study," said Michael McKelvey, President and CEO of eRT. "While many sponsors recognize and source each company for its respective area of expertise, customers increasingly seek consolidation and streamlining in all phases of a clinical trial. eRT and nSpire Health approach the market in the same way -- focusing on scientific excellence, providing a quality product, and client satisfaction. We are both metrics driven and process oriented to ensure on-time, on-budget, reliable data delivery on a global scale."
"Clinical trial sponsors have a strategic need to deliver accurate, cost- effective results in less time. They need therapeutic specialists that they can trust. This partnership leverages the world's most advanced Cardio- Respiratory specific technologies and data management services from each company into one unified source, reducing costs and accelerating time to market for emerging inhaled therapeutic trials," commented Michael S. Sims, President and CEO of nSpire Health, Inc.
About nSpire Health
nSpire Health develops and manufactures respiratory care products and provides related services in over 100 countries. The company is focused on cardiopulmonary diagnostics, respiratory core lab services, and disease management solutions designed to improve health care productivity while increasing the overall quality of patient care. nSpire Health is the exclusive provider of PiKo(R) home health monitors and HDpft(TM) systems, the most accurate and precise pulmonary function testing systems worldwide.
About eRT
Based in Philadelphia, Pa, eResearchTechnology, Inc. (www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE eResearchTechnology, Inc.
